Results 161 to 170 of about 22,433 (204)
Some of the next articles are maybe not open access.
CNS Drugs, 2010
Oral morphine/naltrexone extended release capsules comprise the selective mu-opioid receptor agonist morphine in a sustained-release formulation combined with a sequestered core of the mu-opioid receptor antagonist naltrexone for use in the management of moderate to severe pain.
Sean T, Duggan, Lesley J, Scott
openaire +2 more sources
Oral morphine/naltrexone extended release capsules comprise the selective mu-opioid receptor agonist morphine in a sustained-release formulation combined with a sequestered core of the mu-opioid receptor antagonist naltrexone for use in the management of moderate to severe pain.
Sean T, Duggan, Lesley J, Scott
openaire +2 more sources
NALTREXONE IN CHILDREN WITH AUTISM
Journal of the American Academy of Child & Adolescent Psychiatry, 1998Item does not contain ...
J K, Buitelaar +2 more
openaire +2 more sources
1981
The clinical efficacy of naltrexone together with psychotherapy was compared to that of naltrexone alone in 22 detoxified heroin addicts. The combination of treatments fostered better retention in treatment and greater likelihood of opiate abstinence than naltrexone alone.
N, Stone-Washton +2 more
openaire +2 more sources
The clinical efficacy of naltrexone together with psychotherapy was compared to that of naltrexone alone in 22 detoxified heroin addicts. The combination of treatments fostered better retention in treatment and greater likelihood of opiate abstinence than naltrexone alone.
N, Stone-Washton +2 more
openaire +2 more sources
Journal of Substance Abuse Treatment, 1985
Naltrexone (Trexan R), a long acting, orally affective narcotic antagonist was approved by the Food & Drug Administration in November, 1984 for use as an adjunct in the treatment of Opioid Addiction. This research capsule will explore what is known about naltrexone, and the most appropriate ways of using the drug.
openaire +2 more sources
Naltrexone (Trexan R), a long acting, orally affective narcotic antagonist was approved by the Food & Drug Administration in November, 1984 for use as an adjunct in the treatment of Opioid Addiction. This research capsule will explore what is known about naltrexone, and the most appropriate ways of using the drug.
openaire +2 more sources